Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Califf

Showing results (31-40 of 567) with videos related to

Pageof 57
Sort By:
Circulation|May 21, 1998
What have we learned from the calcium channel blocker controversy?R M Califf, J M Kramer
Diabetes Care|May 8, 1998
Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end pointsR M Califf, C B Granger
Clinical Cardiology|March 1, 1992
Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO InvestigatorsR M Califf, E J Topol
Drugs|November 7, 1999
Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reportsD F Kong, R M Califf
The New England Journal of Medicine|June 16, 1994
Cardiogenic shockR M Califf, J R Bengtson
British Heart Journal|October 1, 1992
Answers to complex questions cannot be derived from "simple" trialsE J Topol, R M Califf
Journal of the American College of Cardiology|July 18, 2000
Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of CardiologyN S Kleiman, R M Califf
American Heart Journal|April 26, 2001
International differences in cardiovascular clinical trialsJ C O'Shea, R M Califf
Lancet (London, England)|May 23, 2000
All that glitters is not goldE J Velazquez, R M Califf
Annals of Internal Medicine|December 1, 1994
The value of exercise thallium imagingK M Zabel, R M Califf
Pageof 57

Showing results (31-40 of 567) with videos related to

Sort By:
Pageof 57
Circulation|May 21, 1998
What have we learned from the calcium channel blocker controversy?R M Califf, J M Kramer
Diabetes Care|May 8, 1998
Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end pointsR M Califf, C B Granger
Clinical Cardiology|March 1, 1992
Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO InvestigatorsR M Califf, E J Topol
Drugs|November 7, 1999
Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reportsD F Kong, R M Califf
The New England Journal of Medicine|June 16, 1994
Cardiogenic shockR M Califf, J R Bengtson
British Heart Journal|October 1, 1992
Answers to complex questions cannot be derived from "simple" trialsE J Topol, R M Califf
Journal of the American College of Cardiology|July 18, 2000
Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of CardiologyN S Kleiman, R M Califf
American Heart Journal|April 26, 2001
International differences in cardiovascular clinical trialsJ C O'Shea, R M Califf
Lancet (London, England)|May 23, 2000
All that glitters is not goldE J Velazquez, R M Califf
Annals of Internal Medicine|December 1, 1994
The value of exercise thallium imagingK M Zabel, R M Califf
Pageof 57